Related Experiment Videos
[Management of lupus nephritis in Senegal]
Insights
Systemic lupus erythematosus, a kidney-affecting disease, is rising in Senegal. Early proteinuria treatment and renal biopsy for suspected impairment are recommended for better lupus nephritis outcomes.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) incidence is increasing in Senegal.
- Renal involvement significantly impacts SLE prognosis, classified by WHO into 6 classes.
- Treatment strategies for lupus nephritis vary based on WHO classification and disease activity.
Observation:
- A 41-year-old female presented with WHO class IV lupus nephritis.
- The patient received an 18-month treatment combining corticosteroids and immunosuppressants.
- A favorable outcome was observed following the treatment regimen.
Findings:
- Class IV lupus nephritis can be effectively managed with a combination of corticosteroids and immunosuppressants.
- Treatment protocols should consider socioeconomic conditions and disease severity.
- Early intervention for proteinuria exceeding 2 mg/24h is suggested.
Implications:
- Renal biopsy is crucial for patients with suspected lupus nephritis.
- Aggressive treatment for WHO class III, IV, and V lupus nephritis is recommended regardless of activity/chronicity indexes.
- Tailoring treatment duration and modality based on clinical and histological features is essential for optimal patient outcomes.
Abstract:
Systemic lupus erythematosus is a disease considered as seldom in Senegal. Nevertheless its incidence is increasing these last years. The prognosis is significantly related to the renal involvement, classified into 6 classes by the WHO. The treatment of these different forms is variable, consisting on abstention or symptomatic treatment for the class III (with low activity index), class II, I, and V (without renal failure). In the other hand a vigorous treatment is indicated in the class III, with consistent activity index, class IV and class V with renal failure. The most frequent of these treatment remains the association using corticosteroids and immunosuppressants. Among immunosuppressants, cyclophosphamide and azathioprine are the most commonly used. The case we reported is about a 41 years old woman who presented a class IV lupic nephropathy, with a good outcome after a 18 months corticosteroid and immunosuppressants association treatment. This case leads us to some recommendations. Considering our poor socioeconomical conditions, we suggest to treat all patients presenting proteinuria higher than 2 mg/24h. However it is more judicious to perform renal biopsy on patients with signs evocating renal impairement and to treat the class III, IV and V whatever would be the degree of activity and chronicity indexes. This treatment must associate immunosuppressive drugs and corticosteroids; the modalities and duration depending on clinical presentation, histologic features and evolution.